CCR5 antagonist
Maraviroc
Brand names: Celsentri
Adult dose
Dose: 150–600mg PO BD per concomitant ARV (refer to BNF)
Route: PO
Frequency: BD
Clinical pearls
- Treatment-experienced HIV-1 with CCR5-tropic virus only
- Tropism assay essential before initiation
Contraindications
- Severe hepatic impairment without adjustment
- CCR5-tropism testing required before use
Side effects
- Hepatotoxicity (severe — black box)
- Postural hypotension
- Increased infection risk
- Cardiac events
- Rash
Interactions
- Many — strong CYP3A4 modulators
- St John's wort
Monitoring
- LFTs
- Tropism assay
- BP
Reference: BNF; BHIVA; SmPC; https://bnf.nice.org.uk/drugs/maraviroc/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023